This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giuffre, A. C. Articles by North, T. W. Search for Related Content PubMed PubMed Citation Articles by Giuffre, A. C. Articles by North, T. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2003, p. 1756-1759, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1756-1759.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Susceptibilities of Simian Immunodeficiency Virus to Protease Inhibitors

Angelica C. Giuffre,¹ Joanne Higgins,¹ Robert W. Buckheit Jr.,^2, and Thomas W. North^1,3*

Center for Comparative Medicine,¹ Department of Veterinary Molecular Biosciences, University of California, Davis, Davis, California 95616,³ Southern Research Institute, Fredrick, Maryland 21701²

Received 29 August 2002/ Returned for modification 18 November 2002/ Accepted 11 February 2003

We used a focal infectivity assay with HeLa H1-JC.37 cells to directly compare susceptibilities of simian immunodeficiency virus (SIV) and human immunodeficiency virus type 1 (HIV-1) to protease inhibitors. SIVmac239 was inhibited by indinavir, saquinavir, and ritonavir, with 50% effective concentrations (means ± standard deviations) of 39 ± 8, 55 ± 3, and 13 ± 5 nM, respectively. The corresponding values for inhibition of HIV-1 were 66 ± 4, 47 ± 10, and 25 ± 14 nM, respectively.

Present address: Infectious Disease, Cancer and Immunology Research Department, TherImmune Research Corporation, Gaithersburg, MD 20879.

This article has been cited by other articles:

• Pandrea, I., Ribeiro, R. M., Gautam, R., Gaufin, T., Pattison, M., Barnes, M., Monjure, C., Stoulig, C., Dufour, J., Cyprian, W., Silvestri, G., Miller, M. D., Perelson, A. S., Apetrei, C. (2008). Simian Immunodeficiency Virus SIVagm Dynamics in African Green Monkeys. J. Virol. 82: 3713-3724 [Abstract] [Full Text]  
• Duong, Y. T., Meadows, D. C., Srivastava, I. K., Gervay-Hague, J., North, T. W. (2007). Direct Inactivation of Human Immunodeficiency Virus Type 1 by a Novel Small-Molecule Entry Inhibitor, DCM205. Antimicrob. Agents Chemother. 51: 1780-1786 [Abstract] [Full Text]  
• Goffinet, C., Allespach, I., Keppler, O. T. (2007). HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. Proc. Natl. Acad. Sci. USA 104: 1015-1020 [Abstract] [Full Text]  
• North, T. W., Van Rompay, K. K. A., Higgins, J., Matthews, T. B., Wadford, D. A., Pedersen, N. C., Schinazi, R. F. (2005). Suppression of Virus Load by Highly Active Antiretroviral Therapy in Rhesus Macaques Infected with a Recombinant Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1. J. Virol. 79: 7349-7354 [Abstract] [Full Text]  
• Hofman, M. J., Higgins, J., Matthews, T. B., Pedersen, N. C., Tan, C., Schinazi, R. F., North, T. W. (2004). Efavirenz Therapy in Rhesus Macaques Infected with a Chimera of Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 48: 3483-3490 [Abstract] [Full Text]